Clinical Trial Detail

NCT ID NCT02983799
Title Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

ovarian endometrial cancer

ovarian serous carcinoma

Therapies

Olaparib

Age Groups: senior adult

No variant requirements are available.